ClinicalTrials.gg
Not yet recruitingNCT07660796Updated Jun 30, 2026

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

A Phase 3 interventional study of HCP1803-3 and HCP1803-4 in Hypertension, sponsored by Hanmi Pharmaceutical Company Limited. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies in Hypertension by Hanmi Pharmaceutical Company Limited — 2 open to participants now, 2 under way, 1 of them phase 3. Hypertension · Hanmi Pharmaceutical Company Limited.

Planned enrollment
5th of 23
256 · median 199
Started
2026
with 1 other
Phase 3
16 of 25
1 open now
Registered
24th of 25
by date

Among the 25 studies in Hypertension by Hanmi Pharmaceutical Company Limited, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 16 in phase 3, and was the 24th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 25 studies in Hypertension by Hanmi Pharmaceutical Company Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hypertension by Hanmi Pharmaceutical Company Limited, or all of them as a file.
02

Study summary

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension

Read the detailed description

A multicenter, randomized, double-blind, phase III study to evaluate efficacy and safety of HCP1803-4 in patients with essential hypertension

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions

    • mean sitSBP \< 180 mmHg and mean sitDBP \< 110 mmHg for patients receiving any BP-lowering drug within 1 month prior to Visit 1
    • 140 mmHg ≤ mean sitSBP \< 180 mmHg and 60 mmHg ≤ mean sitDBP \< 110 mmHg for patients not receiving BP-lowering drugs within 1 month prior to Visit 1
  2. Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP \< 180 mmHg and 60 mmHg ≤ mean sitDBP \< 110 mmHg at Visit 2

Exclusion criteria

Exclusion Criteria:

  1. Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1
  2. Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1
  3. Orthostatic hypotension with symptoms within 3 months prior to visit 1
  4. Secondary hypertensive patient or suspected to be
  5. hematological finding
  6. Severe heart disease or severe neurovascular disease
  7. Moderate or malignant retinopathy
  8. Uncontrolled diabetes mellitus or type I diabetes mellitus
  9. Active gout or hyperuricemia
  10. Severe renal diseases
  11. Severe or active hepatopathy
  12. Hypokalemia or Hyperkalemia
  13. Hyponatremia or Hypernatremia
  14. Hypercalcemia
  15. History of tumor
  16. History of disease
  17. History of alcohol or drug abuse
  18. Positive to pregnancy test, nursing mother, intention on pregnancy
  19. Considered by investigator as not appropriate to participate in the clinical study with other reason
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
256 participants (estimated)

Study arms

  • Experimental
    HCP1803-4

    Take HCP1803-3 once daily for 2 weeks orally, and then take HCP1803-4 once daily for 8 weeks orally.

    Drug: HCP1803-3 · Drug: HCP1803-4

  • Active comparator
    RLD2001-2

    Take RLD2001-1 once daily for 2 weeks orally, and then take RLD2001-2 once daily for 8 weeks orally.

    Drug: RLD2001-1 · Drug: RLD2001-2

Interventions

  • Test drug

  • DrugHCP1803-4

    Test drug

  • DrugRLD2001-1

    Control drug

  • DrugRLD2001-2

    Control drug

06

What researchers measure

Primary outcomes

  1. Change from baseline in sitting systolic blood pressure

    Time frame: Baseline, 10 weeks

Secondary outcomes

  1. Change from baseline in sitting systolic blood pressure

    Time frame: Baseline, 2 weeks, 6 weeks

  2. Change from baseline in sitting diastolic blood pressure

    Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks

  3. Proportion of subjects achieving blood pressure control (sitSBP)

    Time frame: 2 weeks, 6 weeks, 10 weeks

  4. Proportion of subjects achieving blood pressure control (sitSBP, sitDBP)

    Time frame: 2 weeks, 6 weeks, 10 weeks

  5. Blood pressure response rate (sitSBP)

    Time frame: 2 weeks, 6 weeks, 10 weeks

  6. Blood pressure response rate (sitSBP, sitDBP)

    Time frame: 2 weeks, 6 weeks, 10 weeks

  7. Treatment response rate

    Time frame: 2 weeks, 6 weeks, 10 weeks

  8. Change from baseline in pulse pressure

    Time frame: Baseline, 2 weeks, 6 weeks, 10 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Oct 2027, 15 months later.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 15 months is below that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartEst.
Jul 6, 2026
Primary completionEst.
Oct 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07660796
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jul 6, 2026 (estimated)
Primary completion
Oct 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jun 30, 2026

Study contacts

Jee Won Shon
Contact
jeewon.shon@hanmi.co.kr
+82-2-410-9037
Moo-Yong Rhee, M.D., Ph.D.
principal investigator · Donggguk University Ilsan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion